Clinical Trial Update: MB-dNPM1-TCR.1 in Relapsed/Refractory AML [Phase 1, Phase 2]

View source ↗

Summary

Miltenyi Biomedicine is conducting early-phase (Phase 1/2) trials of MB-dNPM1-TCR.1 for relapsed/refractory acute myeloid leukemia, and the study is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• MB-dNPM1-TCR.1

Snippet

Sponsor: Miltenyi Biomedicine GmbH | Conditions: Leukemia, Myeloid, Acute | Phase 1, Phase 2 | Status: RECRUITING